CHF 4.5 million to boost Syrhatech innovation and industrial capacity
Summary
Syrhatech, a French Swiss startup innovating in the development and manufacture of injectable medical devices based on hyaluronic acid, announces the closing of an investment of CHF 4.5 million, completed with strategic investors. The new funds are set to boost the CDMO innovation and industrial capacity.Syrhatech is a French Swiss CDMO (contract development and manufacturing organization) specializing in the development and production of injectable products based on hyaluronic acid and other biopolymers. Founded in 2018 by a very experienced team, the company supports its partners in the R&D, formulation and manufacture of safe and innovative injectable products, primarily marketed as medical devices. With 30 years of experience in the field of Hyaluronic Acid (cross-linked or non-cross-linked) from its founders, SyrhaTech has carved out a comfortable position in hydrogel prefilled syringe manufacturing.Funding for innovation and industrial capacity.This investment will enable Syrhatech to strengthen its R&D team at its site in Geneva and to deploy a new production capacity at its plant in Chamb\xe9ry, France, in order to meet the growing demand of the market for injectable medical devices based on hyaluronic acid, particularly for aesthetic dermatology but also for orthopedics and ophthalmology. It allows us to accelerate our development, strengthen our innovation in hyaluronic acid-based injectable products and increase our production capacity to support the growth of our partners, says Gilles Bos, CEO of Syrhatech.